Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Maximal androgen blockade].

J E Altwein1, B Mohandessi

  • 1Urologische Abteilung, Krankenhaus der Barmherzigen Brüder, München-Nymphenburg.

Der Urologe. Ausg. A
|February 9, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unusually large numbers needed to treat for radical prostatectomy in prostate cancer patients with PSA velocity ≤2 ng/ml/year.

Urologia internationalis·2012
Same author

[LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].

Aktuelle Urologie·2009
Same author

[Primary prevention of bladder cancer. What's new?].

Der Urologe. Ausg. A·2007
Same author

[Local recurrence of prostate cancer: hormone therapy].

Der Urologe. Ausg. A·2006
Same author

Biphosphonates in advanced prostate and renal cell cancer--current status and potential applications.

Urologia internationalis·2006
Same author

[Fortuitous finding microhematuria].

MMW Fortschritte der Medizin·2005
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Maximal androgen blockade (MAB) offers a survival advantage for prostate cancer patients, particularly when combined with LHRH agonists and pure antiandrogens. Its use should be individualized based on prognosis and quality of life.

Area of Science:

  • Oncology
  • Endocrinology
  • Prostate Cancer Research

Context:

  • Androgen deprivation therapy is a cornerstone in prostate cancer treatment.
  • Surgical castration, a common method, leaves residual 5 alpha-dihydrotestosterone.
  • Maximal androgen blockade (MAB) aims to further reduce androgen levels.

Purpose:

  • To evaluate the efficacy and optimal application of Maximal Androgen Blockade (MAB) in prostate cancer.
  • To compare MAB with monotherapy and assess survival and progression benefits.
  • To explore patient selection criteria and quality of life considerations for MAB.

Summary:

  • MAB, combining castration with antiandrogens, effectively lowers dihydrotestosterone-androgen receptor complexes, increasing apoptosis.
  • Phase III trials show MAB provides a 3-6 month survival advantage and delays progression by approximately 6 months compared to monotherapy.

Related Experiment Videos

  • LHRH agonists combined with pure antiandrogens represent the most effective MAB strategy, though side effects and quality of life are concerns.

    • Impact:

    • MAB demonstrates a survival benefit, particularly for patients with minimal metastases or specific prognostic factors.
    • Individualized MAB application, considering prognosis and quality of life, is recommended over general use.
    • Further research into intermittent androgen deprivation and prognosticators is ongoing.